
The latest announcement is out from Voyageur Pharmaceuticals ( ($TSE:VM) ). Voyageur Pharmaceuticals has completed a shares-for-debt settlement totaling $192,300, issuing common shares at a deemed price of $0.155 to
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| VYYRF | Voyageur Pharmaceuticals | 0.08 | -0.04 | -31.01% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.08 | -31.01% |

The latest announcement is out from Voyageur Pharmaceuticals ( ($TSE:VM) ). Voyageur Pharmaceuticals has completed a shares-for-debt settlement totaling $192,300, issuing common shares at a deemed price of $0.155 to

Voyageur Pharmaceuticals ( ($TSE:VM) ) has provided an update. Voyageur Pharmaceuticals Ltd., a Canadian developer of barium and iodine contrast media for medical imaging, is pursuing a vertically integrated model

An announcement from Voyageur Pharmaceuticals ( ($TSE:VM) ) is now available. Voyageur Pharmaceuticals has advanced its proprietary Mueller iodine extraction process, achieving laboratory production of iodine at 99.8% purity with

Voyageur Pharmaceuticals ( ($TSE:VM) ) has provided an announcement. Voyageur Pharmaceuticals has launched a non-brokered private placement to raise between $4 million and $7.5 million through a combination of common

An update from Voyageur Pharmaceuticals ( ($TSE:VM) ) is now available. Voyageur Pharmaceuticals has outlined a strategic roadmap to build a vertically integrated supply chain for barium and iodine contrast

Voyageur Pharmaceuticals ( ($TSE:VM) ) has shared an update. Voyageur Pharmaceuticals has confirmed that barium sulfate sourced from its Frances Creek property meets and exceeds pharmaceutical-grade standards, with independent SGS

The latest update is out from Voyageur Pharmaceuticals ( ($TSE:VM) ). Voyageur Pharmaceuticals has signed a collaboration and funding agreement with Bayer that could provide up to USD 2.35 million

Voyageur Pharmaceuticals ( ($TSE:VM) ) has issued an update. Voyageur Pharmaceuticals has secured 100% ownership of the proprietary “Mueller Process” iodine extraction technology and appointed its inventor, Dr. Brian Mueller,

Voyageur Pharmaceuticals ( ($TSE:VM) ) has provided an announcement. Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling as an independent director to its board, enhancing its strategic positioning for U.S. market

Voyageur Pharmaceuticals ( ($TSE:VM) ) has issued an announcement. Voyageur Pharmaceuticals has signed a non-exclusive distribution agreement with Phalanx, a leading pharmaceutical distributor in Mexico, to expand its market presence
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $18.25M | ― | ― | -0.11 | -6.80 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.